Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
ALLRAllarity Therapeutics(ALLR) Newsfilter·2024-05-07 21:30
  • Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Company Has Paid Off All Bridge Notes in Full Boston (May 7, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced ...